Capecitabine and cisplatin combination is an active and well-tolerated doublet in the treatment of metastatic breast carcinoma patients pretreated with anthracycline and taxanes.

Our aim was to evaluate the activity and toxicity of capecitabine and cisplatin (CapCisp) combination in anthracycline- and taxane-pretreated metastatic breast cancer patients. Thirty-three patients, 20-61 years of age (median 41), were included. They received Cap 2,000 mg/m(2) on days 1-14 and Cisp 60 mg/m(2) on day 1, repeated every 3 weeks. Twelve nonprogressive patients continued single-agent Cap therapy until progression or until intolerable toxicity after Cisp cessation. The disease control rate in 154 cycles was 81.8%: complete response 3.0% (n = 1), partial response 48.5% (n = 16) and stable disease 30.3% (n = 10). The median time to disease progression was 6.3 months (95% CI 3.8-8.8). The median overall survival was 11.5 months (95% CI 6.9-16.1). The only grade 3 toxicity was neutropenia, observed in 4 patients (12.1%). CapCisp has an encouraging anti-tumor activity with a low toxicity rate in anthracycline- and taxane-pretreated metastatic breast cancer patients.

Oksuzoglu B ，Abali H ，Hayran M ，Yildirim N ，Budakoglu B ，Zengin N ... -  《-》

Capecitabine/cisplatin doublet in anthracycline and taxane pretreated and HER-2 negative metastatic breast carcinoma patients.

Ozdemir N ，Aksoy S ，Sendur MA ，Akinci MB ，Yazici O ，Budakoglu B ，Abali H ，Oksuzoglu B ，Zengin N ... -  《Journal of BUON》

Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment.

Thomas ES ，Gomez HL ，Li RK ，Chung HC ，Fein LE ，Chan VF ，Jassem J ，Pivot XB ，Klimovsky JV ，de Mendoza FH ，Xu B ，Campone M ，Lerzo GL ，Peck RA ，Mukhopadhyay P ，Vahdat LT ，Roché HH ... -  《-》

A multicenter phase II trial of docetaxel and capecitabine as salvage treatment in anthracycline- and taxane-pretreated patients with metastatic breast cancer.

Karachaliou N ，Ziras N ，Syrigos K ，Tryfonidis K ，Papadimitraki E ，Kontopodis E ，Bozionelou V ，Kalykaki A ，Georgoulias V ，Mavroudis D ... -  《-》

Prospective study of vinorelbine and capecitabine combination therapy in Chinese patients with metastatic breast cancer pretreated with anthracyclines and taxanes.

This phase II study prospectively evaluated the feasibility of vinorelbine in combination with capecitabine in Chinese patients with metastatic breast cancer (MBC) pretreated with anthracyclines and taxanes. Vinorelbine (25 mg/m(2) intravenous infusion on days 1 and 8) and capecitabine (1,000 mg/m(2) b.i.d., days 1-14) were administered to eligible MBC patients previously treated with anthracyclines and taxanes every 3 weeks for up to 6 cycles, until disease progression or unacceptable toxicity. The primary endpoint was objective response. Seventy-two patients were enrolled. In total, 297 cycles were given (median 4 cycles, range 2-6). The overall response rate was 45.8% (95% CI 34.2-57.4%), including 5 complete (6.9%) and 28 partial responses (38.9%). With median follow-up of 22 months, median time to progression was 7.7 months (95% CI 5.5-10.0) and median survival was 26.1 months (95% CI 19.6-32.6). The response rate was 53.8% in patients resistant to anthracyclines and taxanes combination. The most common hematologic adverse events were leukopenia (81.9%) with grade 3/4 incidence of 41.7%; nausea was the most frequent non-hematologic toxicity (62.5%). Hand-foot syndrome occurred in 12.5% of patients, and diarrhea was rare. Capecitabine 1,000 mg/m(2) b.i.d. combined with vinorelbine 25 mg/m(2) is an effective and safe treatment for MBC patients, no matter if anthracycline and taxane pretreated or resistant.

Fan Y ，Xu B ，Yuan P ，Wang J ，Ma F ，Li Q ，Zhang P ，Li Q ，Cai R ... -  《-》